IMDX Stock Analysis: Buy, Sell, or Hold?
IMDX - Insight Molecular Diagnostics Inc. Common Stock
$4.65
0.05 (1.09%)
▲
5d:
-1.9%
30d:
-18.28%
90d:
+15.96%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 10, 2026
7d
Get Alerted When IMDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMDX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMDX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMDX is currently trading at $4.65, which is considered slightly low relative to its 30-day fair value range of $4.59 to $5.43.
Technical Outlook: Technically, IMDX is in a uptrend. Immediate support is located at $4.35, while resistance sits at $5.20.
Market Sentiment: IMDX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.33 (+79.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMDX is in a uptrend. Immediate support is located at $4.35, while resistance sits at $5.20.
Market Sentiment: IMDX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.33 (+79.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.59 -
$5.43
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 79.2% below Wall St target ($8.33)
Trading Range Analysis
30-Day Trading Range
$4.59 -
$5.43
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.68
(14.7%)
Support & Resistance Levels
Support Level
$4.35
Resistance Level
$5.20
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.96
Wall Street Target
$8.33
(+79.2%)
Revenue Growth (YoY)
-98.5%
Share & Embed Analysis
Last updated: August 02, 2026 5:07 AM ET
Data refreshes hourly during market hours. Next update: 6:07 AM
Data refreshes hourly during market hours. Next update: 6:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMDX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Broadwood Partners, L.P.
BUY
40690 shares
2026-04-20
Broadwood Partners, L.P.
BUY
40114 shares
2026-04-17
Broadwood Partners, L.P.
BUY
102057 shares
2026-04-16
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$615 | 53 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$171 | 61 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 52 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$283 | 59 HOLD |